Download the Protocol

Hexarelin

Hexarelin is a synthetic peptide that mimics ghrelin to increase the body’s natural release of growth hormone. It has been studied for its potential to enhance recovery, improve metabolism, and maintain muscle tissue. It is intended for laboratory research only, not for medical or therapeutic use.

Description

• Hexarelin is a potent growth hormone secretagogue (GHS) and selective ghrelin receptor (GHSR-1a) agonist.
• Developed to stimulate growth hormone (GH) pulses for metabolic and recovery research.
• Non-therapeutic, for research purposes only.

How It Works

• Activates GHSR-1a receptors in the hypothalamus and pituitary to stimulate GH secretion.
• Can increase appetite and improve sleep via central ghrelin signaling pathways.
• Often paired with GHRH analogs (e.g., CJC-1295) for enhanced GH response.

Documented Effects

• Raises GH and IGF-1 levels in animal and early clinical studies.
• Promotes protein synthesis and recovery in preclinical muscle repair models.
• Transient effects may include warmth, flushing, or hunger after injection.

Theoretical Effects

• Potential research use in GH-axis stimulation, anti-aging, and metabolic regulation studies.
• May support tissue recovery and repair in controlled experimental environments.
• Long-term safety and efficacy in humans remain under investigation.

Pharmacokinetics

• Half-life: ~70–90 minutes post-injection.
• Peak GH release: within 30–60 minutes after dosing.
• Duration: transient GH elevation lasting about 2–4 hours.

Duration of Effects

• Stimulates short-term GH release similar to natural pulsatile secretion.
• Effects on metabolism and tissue recovery persist for several hours post-administration.
• Best results achieved with consistent timing across research cycles.

Reconstitution

• Use only bacteriostatic water to reconstitute lyophilized Hexarelin.
• Example vial: 10 mg of Hexarelin
• Choose reconstitution volume based on dosing preference:
  • 1 mL → 10 mg/mL → 1 mg per 10 units
  • 2 mL → 5 mg/mL → 500 mcg per 10 units
• Swirl gently to dissolve; do not shake or foam.
• Refrigerate reconstituted solution (2–8 °C). Use within ~25 days for best stability.

Injectable Dosage Overview (Research Use)

Typical Starting Dose

• 100 mcg subcutaneous (SC) once daily, usually before sleep.
• Start conservatively to observe GH response and tolerance.

Common Research Range

• 100–300 mcg per injection, 1–3× daily depending on study design.
• Often administered in the morning and/or before sleep, or paired with CJC-1295.

Maximum Research Range

• Up to 600 mcg per injection (~900 mcg total daily) reported anecdotally.
• Higher doses show limited added GH response due to receptor saturation.

Standard Cycle Length

• 8–12 weeks of use followed by an equal-length rest period.
• Intermittent dosing preserves receptor sensitivity.

Clinical Notes

• Potent GH secretagogue; significantly stronger than GHRP-6 and GHRP-2 in GH pulse amplitude.
• Administer subcutaneously; rotate sites to avoid localized irritation.
• Inject on an empty stomach, as glucose and insulin blunt GH response.
• May cause transient flushing, lightheadedness, or strong hunger due to ghrelin-receptor activation.
• Long-term or high-dose use can lead to partial desensitization of GH receptors; best used in cycles.
• Stable for about 25 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes (First-Time Use)

• May cause short-term hunger, lightheadedness, or flushing.
• Always use sterile technique and verify compound authenticity.
• For research purposes only; not for therapeutic human use.